GMDP
Alternative Names: Glucosaminyl muramyl dipeptide; Glycopin; LicopidLatest Information Update: 19 Mar 2003
At a glance
- Originator Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry
- Developer Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry; ZAO Peptech; ZAO Peptek
- Class Antineoplastics; Antipsoriatics; Antivirals; Dipeptides; Glycopeptides; Muramic acids
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Herpesvirus infections; Lung disorders; Postoperative infections; Psoriasis; Respiratory tract disorders; Tuberculosis
- No development reported Neutropenia; Pyoderma
Most Recent Events
- 19 Mar 2003 No development reported - Phase-II for Neutropenia (Chemotherapy-induced, Prevention) in Australia, Russia and the UK (PO)
- 19 Mar 2003 No development reported - Phase-II for Postoperative infections (Prevention) in Australia, Russia and the UK (PO)
- 19 Mar 2003 No development reported - Phase-II for Psoriasis in United Kingdom (PO)